AGENUS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.69 USD | +40.84% |
|
+120.15% | -29.40% |
| Apr. 12 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
| Apr. 12 | Sector Update: Health Care | MT |
Financials (USD)
| Sales 2024 * | 284M | Sales 2025 * | 199M | Capitalization | 245M |
|---|---|---|---|---|---|
| Net income 2024 * | -154M | Net income 2025 * | -269M | EV / Sales 2024 * | 0.86 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1.23 x |
| P/E ratio 2024 * |
-1.51
x | P/E ratio 2025 * |
-0.91
x | Employees | 389 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Agenus Inc.
More recommendations
More press releases
| 1 day | +40.84% | ||
| 1 week | +120.15% | ||
| Current month | +0.78% | ||
| 1 month | +8.97% | ||
| 3 months | -11.79% | ||
| 6 months | -27.84% | ||
| Current year | -29.40% |
1 week
4.91
12.23
1 month
4.7812.23
Current year
4.7818.98
1 year
4.7842.60
3 years
4.78135.80
5 years
4.78135.80
10 years
4.78203.20
| Managers | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director of Finance/CFO | 58 | 95-12-31 | |
Craig Winter
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Garo Armen
CEO | Chief Executive Officer | 71 | 94-03-30 |
| Director/Board Member | 66 | 16-05-16 | |
Susan Hirsch
BRD | Director/Board Member | 71 | 20-10-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.15% | 27 M€ | -5.03% | - | |
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 11.69 | +40.84% | 3,367,371 |
| 24-04-25 | 8.3 | +11.86% | 961,370 |
| 24-04-24 | 7.42 | +14.86% | 1,274,190 |
| 24-04-23 | 6.46 | +11.96% | 1,688,559 |
| 24-04-22 | 5.77 | +8.66% | 900,544 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT
More quotes
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
11.69
USD
Average target price
88.75
USD
Spread / Average Target
+659.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.40% | 245M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- AGEN Stock
